A fluorinated arylboronic acid ester compound, its preparation method and application

By heating the reaction system under nitrogen or argon protection with a base-promoted reaction system, the ortho-CH bond boronization of fluorinated aromatics was achieved, solving the problems of harsh conditions and high costs in traditional methods, and providing a highly selective and efficient synthetic route for fluorinated aryl borate esters.

CN123062471APending Publication Date: 2026-11-10XUZHOU NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611437057.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-16
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies require harsh ultra-low temperature conditions and highly active organometallic reagents, or rely on expensive noble metal catalysts, when synthesizing fluorinated arylboronic esters, and the regioselectivity is difficult to control.

Method used

A base-promoted reaction system was adopted, using bis(4,4,5,5-tetraethyl-1,3,2-dioxaborane-2-yl)methane as a raw material. The reaction was carried out under nitrogen or argon protection and heated to achieve the ortho-CH bond boronization of fluoroaromatics, thus avoiding the use of transition metal catalysts.

Benefits of technology

This method enables highly regioselective boration of fluorinated aromatics under mild conditions, reducing synthesis costs, improving substrate applicability and product conversion potential, and is suitable for late-stage modification of various functional groups, providing a synthetic route for fluorine-containing functional molecules.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123062471A_ABST
    Figure CN123062471A_ABST
Patent Text Reader

Abstract

This invention discloses a fluorinated aryl borate ester compound, its preparation method, and its applications. The compound has the structural formula shown in Formula I, characterized by a borate ester group attached to the ortho position of a fluorine atom in the aryl ring. Specifically, the borate ester group is preferably a tetraethyl-substituted 1,3,2-dioxaborane derivative with high steric hindrance and good stability; Ar is a benzene ring or a naphthalene ring, and R is hydrogen, halogen, alkoxy, alkyl, acyloxy, aryl, siloxy, or ester. This compound is structurally stable, can be stored at room temperature, and can be prepared without a metal catalyst. Furthermore, this compound can serve as a multifunctional synthetic building block, converting to halogen atoms such as bromine, chlorine, and iodine, or aryl groups via a one-pot borate esterification process, thereby efficiently preparing various fluorinated aryl derivatives. This invention offers good yields, high regioselectivity, and simple operation, making it valuable for the synthesis of fluorinated fine chemicals and pharmaceutical intermediates.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of organic synthesis technology, specifically to a fluorinated arylboronic acid ester compound, its preparation method, and its application. Background Technology

[0002] Arylboronic acids and their esters are fundamental chemicals and building blocks in organic synthesis. They exhibit excellent reactivity in transition metal-catalyzed cross-coupling reactions (such as the Suzuki-Miyaura coupling reaction) and are widely used in the synthesis of pharmaceuticals, pesticides, natural products, and functional materials. Among these, fluorinated arylboronic esters, possessing both the unique physicochemical properties of fluorine atoms and the rich reactivity of boronic esters, are of significant value in the synthesis of fluorinated drugs and fluorinated functional molecules. With the increasing demand for fluorinated drugs and materials, the development of efficient synthetic methods for fluorinated arylboronic esters has become a research hotspot in the field of organic synthesis and synthetic chemistry.

[0003] Traditional methods for synthesizing fluorinated arylboronic esters mainly fall into two categories: one is the route involving halogenation, lithiation, and subsequent boration of fluorinated aromatics; the other is the CH bond activation boration route catalyzed by expensive transition metal complexes such as iridium (Ir). However, these methods have significant limitations: the former often requires extremely harsh ultra-low temperature conditions and highly reactive organometallic reagents, resulting in poor functional group compatibility; the latter, while operating under relatively milder conditions, heavily relies on expensive noble metal catalysts and special ligands, and often faces difficulties in controlling regioselectivity in polysubstituted aromatic substrates.

[0004] Therefore, developing a mild, transition metal-free, and highly regioselective direct ortho-CH bond boronization method for fluoroaromatics is of great significance for the efficient preparation of fluoroaryl boronic esters and is also a problem that urgently needs to be solved in the field of synthetic chemistry. Summary of the Invention

[0005] The purpose of this invention is to provide a fluorinated aryl borate ester compound, its preparation method, and its applications. This method does not require expensive transition metal catalysts; it only utilizes a base-promoted reaction system to achieve precise CH bond borylation of fluorinated aromatic hydrocarbons at the ortho position of fluorine atoms. The prepared compound possesses both the unique physicochemical properties of fluorine atoms and the rich reactivity of borate esters, exhibiting high synthetic value and serving as a key intermediate. Applying this compound to the preparation of fluorinated aryl derivatives allows for the efficient construction of structurally diverse fluorinated functional molecules through various functional group transformations, providing an effective pathway for the synthesis of fluorinated functional molecules.

[0006] The first aspect of the present invention is to provide a fluorinated arylboronic acid ester compound having the structure shown in Formula I: ; The structure is characterized by a borate ester group attached to the ortho position of the fluorine atom in the aryl ring. Specifically, the borate ester group is preferably a tetraethyl-substituted 1,3,2-dioxaborane derivative with high steric hindrance and good stability; in Formula I: R is selected from hydrogen, halogen, alkoxy, alkyl, acyloxy, aryl, siloxy, or ester; Ar is a benzene ring or a naphthalene ring.

[0007] Preferably, R is hydrogen, fluorine, chlorine, an alkoxy group with 1-6 carbon atoms, an acyloxy group with 1-7 carbon atoms, an alkyl group with 1-6 carbon atoms, a benzene ring containing a chemically acceptable substituent, a pyridine ring containing a chemically acceptable substituent, a pyrrole ring containing a chemically acceptable substituent, tert-butyldimethylsiloxy, triisopropylsiloxy, an alkoxycarbonyl group with 1-6 carbon atoms, or an alkylcarbamoyl group with 1-7 carbon atoms.

[0008] A second aspect of the present invention is to provide a method for preparing the above-mentioned fluorinated arylboronic acid ester compound, the specific steps of which are: Under nitrogen / argon protection, in a solvent, a fluorinated aryl base compound of formula II and a compound of formula III, bis(4,4,5,5-tetraethyl-1,3,2-dioxaborpentane-2-yl)methane (abbreviated as (BEpin)2CH2), are reacted under the promotion of an alkali in an organic solvent by heating. The resulting reaction solution is then post-treated to obtain the fluorinated aryl borate ester compound shown in formula I. The structural formula of the fluorinated aromatic base material of compound II is as follows: ; The structural formula of compound III, bis(4,4,5,5-tetraethyl-1,3,2-dioxaborone-2-yl)methane, is as follows: ; Wherein, R is selected from hydrogen, halogen, alkoxy, alkyl, acyloxy, aryl, siloxy, ester or amide; Ar is a benzene ring, naphthyl ring or pyridine ring.

[0009] The reaction equation for the above reaction process is shown in Reaction Equation I below:

[0010] Reaction formula I.

[0011] Preferably, the molar ratio between the fluorinated aromatic base of Formula II, the bis(4,4,5,5-tetraethyl-1,3,2-dioxaborane-2-yl)methane of Formula III, and the base is 1:(2-3):(1-2); more preferably 1:2:2.

[0012] Preferably, the temperature of the heating reaction is 80-120°C. o C, preferably 120 oC; The heating reaction time is 5-24 hours, preferably 12 hours.

[0013] Preferably, the alkali is one or more of NaOtBu, KOtBu, NaOMe, KOMe, KOAc, KHMDS, or NaHMDS; preferably, it is KOtBu.

[0014] Preferably, the organic solvent is one or more of tetrahydrofuran (THF), dimethyl ethylene glycol (DME), diethylene glycol dimethyl ether (diglyme), 1,4-dioxane (1,4-dioxane), or toluene; preferably, it is dimethyl ethylene glycol (DME).

[0015] Under the above conditions, the reaction does not require any transition metal catalyst and exhibits excellent ortho-specific selectivity for fluorine atoms, that is, the borylation process specifically occurs on the ortho-CH bond of an existing fluorine atom.

[0016] The third aspect of this invention is to provide the application of the above-mentioned fluorinated arylboronic acid ester compound as a synthetic intermediate in the preparation of fluorinated aryl derivatives; this compound has extremely high reactivity and can be used to synthesize a series of fluorinated aryl derivatives with important application value through various transformation conditions. Taking fluorinated aromatic hydrocarbons as substrates (i.e., R is selected from hydrogen and Ar is a benzene ring) as an example, as shown in the following reaction formula II, the synthesized fluorinated arylboronic acid ester compound (central molecule) is transformed into various downstream products such as various fluorinated haloaromatic hydrocarbons and biphenyl derivatives.

[0017] Specifically, including but not limited to: Chlorination conversion: using CuCl2 in MeOH / H2O at 90°C o The C reaction converts the carbon-boron bond into a carbon-chlorine bond, yielding o-fluorochloroaromatics.

[0018] Bromination conversion: utilizing CuBr2 in MeOH / H2O at 90°C o The C reaction converts the carbon-boron bond into a carbon-bromine bond, yielding o-fluorobromoaromatic hydrocarbons.

[0019] Iodination conversion: using NaI and chloramine-T in THF / H2O at 70°C o The C reaction converts the carbon-boron bond into a carbon-iodine bond, yielding o-fluoroiodoaryl hydrocarbons.

[0020] Suzuki cross-coupling: Biphenyl structures were constructed by coupling with iodobenzene in a catalytic system of palladium acetate (Pd(OAc)2), 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl (SPhos) and K3PO4.

[0021]

[0022] Reaction formula II; In reaction formula II, BEpin represents .

[0023] Compared with the prior art, the beneficial effects of the present invention are as follows: First, it is green and economical, and the conditions are mild: This invention avoids the dependence of traditional CH bond borylation on noble metal (such as Ir, Rh) catalysts, and adopts an inexpensive and readily available base-promoted system, which greatly reduces the synthesis cost.

[0024] Second, high regioselectivity: In multi-substituted aromatic systems, this method exhibits a significant selective preference for the CH bond adjacent to the fluorine atom, solving the problem of difficult-to-control site selectivity in traditional methods.

[0025] Third, the reaction has broad substrate applicability and the ability to perform late-stage modifications: it is not only applicable to simple fluoroaromatics, but can also be successfully applied to the late-stage functionalization of precursor molecules with complex skeletons.

[0026] Fourth, the product has great potential for transformation: the carbon-boron bonds in the product can be efficiently and stably transformed into carbon-halogen bonds (C-Cl, C-Br, CI) and carbon-carbon bonds (C-Cl), providing a powerful platform molecule for the rapid construction of fluorine-containing drug libraries. Detailed Implementation

[0027] The present invention will be further described in detail below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Modifications or substitutions made to the methods, steps, or conditions of the present invention without departing from the spirit and substance of the invention are all within the protection scope of the present invention.

[0028] Example 1

[0029] A fluorinated arylboronic acid ester compound, the structural formula of which is The preparation method of this fluorinated arylboronic ester compound is as follows: In a glove box filled with dry nitrogen or argon gas, the following compounds are added sequentially to a reaction tube: [Structure formula omitted] The reaction mixture contained a fluorinated aromatic base (1.0 mmol), compound III bis(4,4,5,5-tetraethyl-1,3,2-dioxaborane-2-yl)methane (BEpin)2CH2 (2.0 mmol), potassium tert-butoxide (KOtBu) (2.0 mmol), and dried ethylene glycol dimethyl ether (DME) (3 mL). After sealing the reaction tube, the mixture was removed from room temperature and heated to 120°C in an oil bath. oC. Stir the reaction mixture for 12 hours. After the reaction is complete, cool the mixture to room temperature, quench the reaction with saturated ammonium chloride aqueous solution, and extract several times with ethyl acetate. Combine the organic phases, dry with anhydrous sodium sulfate, filter, and concentrate under reduced pressure to remove the solvent. The crude product is purified by silica gel column chromatography to obtain the ortho-boronized product with high regioselectivity.

[0030] The preparation methods of Examples 2-19 only changed the fluorinated aromatic substrate, while the other steps and process conditions remained the same as in Example 1.

[0031] The structures of the fluorinated aromatic base compounds of Formula II used in Examples 1-19 and the fluorinated arylboronic acid ester compounds of Formula I prepared are shown in Table 1 below: Table 1. Structural formulas of the fluorinated aromatic substrates in Examples 1-19 and the prepared fluorinated arylboronic acid ester compounds.

[0032] The products obtained in all Examples 1-19 above were obtained through... 1 H-NMR, 13 C-NMR characterization confirmed this, and the specific results are as follows: The NMR data of the product obtained in Example 1 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.73 (q, J =8.2, 7.4 Hz, 1H), 6.86 (t, J = 8.3 Hz, 1H), 6.76 (t, J = 9.3 Hz, 1H), 1.77(tp, J = 14.3, 7.8, 7.3 Hz, 8H), 0.97 (t, J = 7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 169.42 - 169.17 (m), 167.12 - 166.47 (m), 164.31 (d, J = 12.3 Hz), 138.23 (t, J = 10.1 Hz), 111.17 (dd, J = 20.2, 3.5 Hz), 103.76 (dd, J = 27.7,24.4 Hz), 89.08, 26.45, 8.90. The NMR data of the product obtained in Example 2 are as follows: 1H NMR (400 MHz, CDCl3) δ 7.79 - 7.71(m, 1H), 6.86 (t, J = 8.4 Hz, 1H), 1.85 - 1.68 (m, 8H), 0.97 (t, J = 6.8 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 167.29 (d, J = 10.5 Hz), 164.76 (d, J = 10.5Hz), 161.59 (d, J = 12.9 Hz), 159.06 (d, J = 12.9 Hz), 137.96 (d, J = 9.9Hz), 116.44 (dd, J = 17.0, 4.1 Hz), 105.20 (dd, J = 29.4, 23.8 Hz), 89.53, 26.50, 8.94. The NMR data of the product obtained in Example 3 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.51 (d, J =5.2 Hz, 1H), 7.24 - 7.16 (m, 1H), 6.90 (t, J = 8.6 Hz, 1H), 2.31 (s, 3H),1.88 - 1.66 (m, 8H), 0.98 (t, J = 7.3 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ165.64 (d, J = 248.3 Hz), 137.04 (d, J = 7.9 Hz), 133.72 (d, J = 8.4 Hz), 132.88 (d, J = 3.1 Hz), 115.07 (d, J = 24.0 Hz), 88.99, 26.54, 20.61, 9.00. 19 F NMR (376 MHz, CDCl3) δ -108.3. The NMR data of the product obtained in Example 4 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.43 - 7.34(m, 1H), 7.08 (q, J = 5.7, 4.9 Hz, 1H), 6.97 (td, J = 8.1, 3.2 Hz, 1H), 1.86- 1.68 (m, 8H), 0.97 (t, J = 7.4 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 163.12(d, J = 247.4 Hz), 158.55 (d, J = 242.0 Hz), 122.35 (dd, J = 22.3, 9.0 Hz), 119.64 (dd, J = 24.3, 9.3 Hz), 116.68 (dd, J = 27.3, 7.9 Hz), 89.41, 26.50,8.94. 19 F NMR (376 MHz, CDCl3) δ -109.38 (d, J = 19.6 Hz), -120.68 (d, J =19.4 Hz). The NMR data of the product obtained in Example 5 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.97 - 7.90(m, 1H), 7.67 - 7.60 (m, 1H), 7.57 (d, J = 7.3 Hz, 2H), 7.44 (t, J = 7.3 Hz,2H), 7.34 (t, J = 7.2 Hz, 1H), 7.10 (t, J = 8.5 Hz, 1H), 1.90 - 1.70 (m, 8H), 1.00 (t, J = 7.2 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 167.03 (d, J = 251.6Hz), 140.49, 136.91 (d, J = 3.4 Hz), 135.58 (d, J = 8.4 Hz), 131.93 (d, J =8.8 Hz), 128.88, 127.27 (d, J = 2.4 Hz), 115.75 (d, J = 24.3 Hz), 89.16, 26.56, 9.02. 19 F NMR (376 MHz, CDCl3) δ -105.5. The NMR data of the product obtained in Example 6 are as follows: 1H NMR (400 MHz, CDCl3) δ 7.76 - 7.71(m, 1H), 7.58 (t, J = 1.6 Hz, 1H), 7.56 (q, J = 1.5 Hz, 1H), 7.55 - 7.49 (m,1H), 7.46 - 7.40 (m, 2H), 7.38 - 7.33 (m, 1H), 7.22 (t, J = 7.4 Hz, 1H), 1.89- 1.71 (m, 8H), 1.00 (t, J = 7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 164.0(d, J = 253.1 Hz), 136.2, 136.1, 134.1 (d, J = 4.1 Hz), 129.3 (d, J = 2.9Hz), 129.1 (d, J = 15.9 Hz), 128.4, 127.6, 124.0 (d, J = 3.8 Hz), 89.1, 26.6,9.0. 19 F NMR (376 MHz, CDCl3) δ -107.78. The NMR data of the product obtained in Example 7 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.74 (t, J =6.4 Hz, 1H), 7.56 (d, J = 7.8 Hz, 2H), 7.51 (d, J = 7.6 Hz, 1H), 7.43 (t, J =7.6 Hz, 2H), 7.37 (t, 1H), 7.22 (t, J = 7.4 Hz, 1H), 1.89 - 1.71 (m, 8H), 1.00 (t, J = 7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 164.0 (d, J = 253.0 Hz), 136.2, 136.1, 134.1 (d, J = 4.1 Hz), 129.3 (d, J = 2.8 Hz), 129.1 (d, J =15.8 Hz), 128.4, 127.6, 124.0 (d, J = 3.8 Hz), 89.1, 26.6, 9.0. 19 F NMR (376MHz, CDCl3) δ -107.80. The NMR data of the product obtained in Example 8 are as follows:1 H NMR (400 MHz, CDCl3) δ 8.16 (d, J =7.9 Hz, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.77 - 7.70 (m, 1H), 7.60 (d, J = 8.3Hz, 1H), 7.54 (p, J = 6.8 Hz, 2H), 1.93 - 1.72 (m, 8H), 1.02 (t, J = 7.4 Hz,12H). 13 C NMR (101 MHz, CDCl3) δ 164.14 (d, J = 249.3 Hz), 139.14 (d, J = 9.3Hz), 136.16 (d, J = 9.8 Hz), 130.19, 128.65, 127.90, 127.10 (d, J = 5.3 Hz), 125.06 (d, J = 2.4 Hz), 110.66 (d, J = 23.1 Hz), 89.22, 26.60, 9.04. 19 F NMR (376 MHz, CDCl3) δ -110.7. The NMR data of the product obtained in Example 9 are as follows: 1 H NMR (400 MHz, CDCl3) δ 8.31 (d, J =5.9 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.51 (t, J =7.8 Hz, 1H), 7.42 (t, J = 8.3 Hz, 2H), 1.89 - 1.75 (m, 8H), 1.02 (t, J = 7.4Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 164.1 (d, J = 249.3 Hz), 139.1 (d, J =9.4 Hz), 136.2 (d, J = 9.8 Hz), 130.2, 128.3 (d, J = 75.4 Hz), 127.1 (d, J =5.4 Hz), 125.1, 125.1, 110.7 (d, J = 23.1 Hz), 89.2, 26.6, 9.0. 19 F NMR (376MHz, CDCl3) δ -107.34. The NMR data of the product obtained in Example 10 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.92 (dt, J =5.0, 2.3 Hz, 1H), 7.65 - 7.58 (m, 1H), 7.47 (d, J = 7.4 Hz, 2H), 7.25 (d, J =8.0 Hz, 2H), 7.08 (t, J = 8.6 Hz, 1H), 2.40 (s, 3H), 1.89 - 1.70 (m, 8H), 1.00 (t, J = 7.4 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 166.86 (d, J = 251.1Hz), 137.62, 137.03, 136.83 (d, J = 3.4 Hz), 135.36 (d, J = 8.3 Hz), 131.73(d, J = 8.8 Hz), 129.58, 127.08, 115.67 (d, J = 24.3 Hz), 89.12, 26.55,21.22, 9.01. The NMR data of the product obtained in Example 11 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.93 - 7.87(m, 1H), 7.62 - 7.55 (m, 1H), 7.51 (d, J = 8.3 Hz, 2H), 7.08 (t, J = 8.7 Hz,1H), 6.98 (d, J = 8.3 Hz, 2H), 3.85 (s, 3H), 1.90 - 1.71 (m, 8H), 1.00 (t, J= 7.4 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 166.66 (d, J = 250.9 Hz), 159.15,136.51 (d, J = 3.3 Hz), 135.07 (d, J = 8.3 Hz), 133.04, 131.49 (d, J = 8.7Hz), 128.24, 115.65 (d, J = 24.3 Hz), 114.28, 89.10, 55.46, 26.54, 9.00. The NMR data of the product obtained in Example 12 are as follows: 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J =8.1 Hz, 1H), 7.90 - 7.81 (m, 3H), 7.49 (ddd, J = 27.4, 15.8, 6.1 Hz, 5H), 7.16 (t, J = 8.6 Hz, 1H), 1.90 - 1.71 (m, 8H), 0.99 (t, J = 7.4 Hz, 12H). 13 CNMR (101 MHz, CDCl3) δ 166.82 (d, J = 251.3 Hz), 139.39, 138.28 (d, J = 8.2Hz), 136.25 (d, J = 3.4 Hz), 134.76 (d, J = 8.7 Hz), 133.89, 131.87, 128.41,127.85, 127.20, 126.23, 126.02, 125.93, 125.47, 115.20 (d, J = 24.2 Hz),89.16, 26.53, 8.98. The NMR data of the product obtained in Example 13 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.73 - 7.66(m, 1H), 7.40 (d, J = 5.4 Hz, 1H), 6.98 (t, J = 8.7 Hz, 1H), 4.63 (d, J =11.3 Hz, 1H), 4.35 (d, J = 11.3 Hz, 1H), 3.21 - 3.09 (m, 1H), 2.35 - 2.24 (m,1H), 2.18 (d, J = 11.9 Hz, 1H), 1.86 - 1.63 (m, 10H), 1.30 (dd, J = 23.9,12.6 Hz, 2H), 1.02 - 0.88 (m, 21H), 0.70 (d, J = 7.0 Hz, 3H). 13C NMR (101MHz, CDCl3) δ 166.82 (d, J = 250.4 Hz), 136.45 (d, J = 8.4 Hz), 134.42 (d, J= 3.1 Hz), 132.89 (d, J = 8.8 Hz), 115.27 (d, J = 24.2 Hz), 89.03, 78.93,69.79, 48.45, 40.46, 34.70, 31.69, 26.54, 25.65, 23.37, 22.50, 21.14, 16.19,8.96. The NMR data of the product obtained in Example 14 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.88 (dd, J =5.6, 2.4 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.58 - 7.52 (m, 1H), 7.36 (d, J =8.2 Hz, 1H), 7.29 - 7.22 (m, 1H), 7.18 - 7.10 (m, 2H), 6.56 (s, 1H), 3.72 (s,3H), 1.89 - 1.71 (m, 8H), 1.00 (t, J = 7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3)δ 167.1 (d, J = 252.7 Hz), 139.5 (d, J = 236.4 Hz), 138.0 (d, J = 8.6 Hz), 134.1 (d, J = 9.1 Hz), 128.6, 128.5, 128.0, 121.8, 120.6, 120.0, 115.6 (d, J= 24.5 Hz), 109.7, 101.8, 89.3, 31.2, 26.5, 9.0. 19 F NMR (376 MHz, CDCl3) δ -103.56. The NMR data of the product obtained in Example 15 are as follows: 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J =5.5, 2.6 Hz, 1H), 7.57 - 7.51 (m, 1H), 7.07 (d, J = 8.7 Hz, 1H), 7.05 (d, J =1.8 Hz, 1H), 7.04 - 7.01 (m, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.00 (s, 2H), 1.88 - 1.70 (m, 8H), 0.99 (t, J = 7.4 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ166.8 (d, J = 251.3 Hz), 148.2, 147.1, 136.6 (d, J = 3.4 Hz), 135.2 (d, J =8.3 Hz), 134.9, 131.6 (d, J = 8.7 Hz), 120.7, 115.7 (d, J = 24.3 Hz), 108.7,107.8, 101.3, 89.2, 26.6, 9.0. 19 F NMR (376 MHz, CDCl3) δ -105.86. The NMR data of the product obtained in Example 16 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.36 (t, J =7.7 Hz, 3H), 7.32 (d, J = 7.7 Hz, 1H), 7.29 - 7.25 (m, 2H), 7.00 - 6.89 (m,2H), 3.58 (s, 2H), 3.14 (t, 4H), 2.62 (t, 4H), 1.86 - 1.68 (m, 8H), 0.97 (t,J = 7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 161.8 (d, J = 244.3 Hz), 147.6,138.0, 129.4, 128.4, 127.3, 124.4 (d, J = 8.0 Hz), 121.5 (d, J = 8.4 Hz), 115.7 (d, J = 25.1 Hz), 89.0, 63.1, 53.3, 26.5, 9.0. 19 F NMR (376 MHz, CDCl3)δ -114.21. The NMR data of the product obtained in Example 17 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.42 (dd, J =4.6, 3.0 Hz, 1H), 7.34 - 7.28 (m, 2H), 7.09 - 7.03 (m, 2H), 7.00 (t, J = 8.5Hz, 1H), 6.97 - 6.93 (m, 2H), 1.86 - 1.68 (m, 8H), 0.97 (t, J = 7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 163.4 (d, J = 247.2 Hz), 158.2, 152.1 (d, J = 2.6Hz), 129.8, 127.5 (d, J = 8.6 Hz), 124.2 (d, J = 9.1 Hz), 122.9, 117.9, 116.6(d, J = 26.3 Hz), 89.3, 26.5, 8.9. 19 F NMR (376 MHz, CDCl3) δ -109.47. The NMR data of the product obtained in Example 18 are as follows: 1 H NMR (400 MHz, CDCl3) δ 7.72 (dd, J= 4.8, 3.0 Hz, 1H), 7.44 - 7.38 (m, 1H), 7.08 (t, J = 8.5 Hz, 1H), 7.03 (t, J= 2.2 Hz, 2H), 6.33 (t, J = 2.2 Hz, 2H), 1.87 - 1.69 (m, 8H), 0.98 (t, J =7.5 Hz, 12H). 13 C NMR (101 MHz, CDCl3) δ 165.1 (d, J = 250.2 Hz), 136.9 (d, J = 3.0 Hz), 128.9 (d, J = 8.7 Hz), 125.6 (d, J = 9.1 Hz), 119.9, 116.4 (d, J =25.8 Hz), 110.4, 89.4, 26.5, 9.0. 19 F NMR (376 MHz, CDCl3) δ -106.71. The NMR data of the product obtained in Example 19 are as follows: 1H NMR (400 MHz, CDCl3) δ 8.66 (s, 2H),8.03 - 7.93 (m, 1H), 7.74 - 7.63 (m, 1H), 7.50 (s, 2H), 7.14 (t, J = 8.4 Hz,1H), 1.88 - 1.70 (m, 8H), 0.99 (t, J = 7.1 Hz, 12H). 13 C NMR (101 MHz, CDCl3)δ 168.0 (d, J = 254.3 Hz), 150.3, 147.6, 135.6 (d, J = 8.7 Hz), 133.8 (d, J =3.5 Hz), 131.8 (d, J = 9.2 Hz), 121.7, 116.3 (d, J = 24.5 Hz), 89.4, 26.6,9.0. 19 F NMR (376 MHz, CDCl3) δ -102.17. Example 20: The application of fluorinated arylboronic acid esters in the synthesis of o-fluorochloroaromatics, as detailed below:

[0033] The fluorinated arylboronic ester compound (0.5 mmol) prepared in Example 5 was converted at 90 °C in a MeOH / H2O (1 / 1, 3 mL) system using CuCl2 (2.0 mmol) as the chlorine source. After separation and purification, the corresponding o-fluorochloroaromatic product was obtained in 80% yield. 1 H NMR (400 MHz, CDCl3) δ7.76 (dd, J = 5.0, 2.2 Hz, 1H), 7.62 - 7.57 (m, 2H), 7.54 - 7.49 (m, 1H),7.47 - 7.42 (m, 2H), 7.41 - 7.35 (m, 1H), 7.28 (t, J = 8.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 159.19 (d, J = 252.1 Hz), 139.81, 137.08 (d, J = 3.1 Hz), 129.00, 128.94 (d, J = 7.9 Hz), 127.92, 126.98 (d, J = 8.1 Hz), 126.76,122.43 (d, J = 20.0 Hz), 117.00 (d, J = 20.0 Hz). Example 21: The application of fluorinated arylboronic acid esters in the synthesis of o-fluorobromoaromatics, as detailed below:

[0034] The fluorinated arylboronic ester compound (0.5 mmol) prepared in Example 5 was converted at 90 °C in a MeOH / H2O (1 / 1, 3 mL) system using CuBr2 (2.0 mmol) as the bromine source. After separation and purification, the corresponding o-fluorobromoaromatic product was obtained in 62% yield. 1 H NMR (100 MHz, CDCl3) δ7.85 (dd, J = 5.0, 2.2 Hz, 1H), 7.62 - 7.57 (m, 2H), 7.52 - 7.47 (m, 1H),7.47 - 7.42 (m, 2H), 7.41 - 7.34 (m, 1H), 7.25 (t, J = 8.1 Hz, 1H). 13 C NMR(101 MHz, CDCl3) δ 160.63 (d, J = 251.8 Hz), 140.57, 137.60 (d, J = 3.1 Hz), 132.41 (d, J = 7.9 Hz), 129.06, 127.92, 127.82 (d, J = 8.1 Hz), 127.37,116.66 (d, J = 20.0 Hz), 109.82 (d, J = 19.8 Hz). Example 22: The application of fluorinated arylboronic acid esters in the synthesis of o-fluoroiodoaromatics, as detailed below:

[0035] The fluorinated arylboronic ester compound (0.5 mmol) prepared in Example 5 was dissolved in a mixed solvent of tetrahydrofuran and water (4 mL, 1:1), and NaI (1.0 mmol) and chloramine-T (1.0 mmol) were added sequentially. The mixture was stirred at 70 °C. After extraction and washing, the product was purified by column chromatography to obtain the o-fluoroiodoaryl product with a separation yield of 85%. 1 H NMR (100 MHz, CDCl3) δ 8.16 (dd, J = 5.0, 1.9 Hz, 1H), 7.62 - 7.57(m, 2H), 7.57 - 7.51 (m, 1H), 7.48 - 7.41 (m, 2H), 7.41 - 7.35 (m, 1H), 7.18(t, J = 8.0 Hz, 1H). 13 C NMR (101 MHz, CDCl3) δ 162.25 (d, J = 252.1 Hz), 138.62 (d, J = 7.9 Hz), 138.33, 138.20 (d, J = 3.1 Hz), 129.06, 128.42 (d, J= 7.9 Hz), 127.92, 127.24, 116.01 (d, J = 20.0 Hz), 84.02 (d, J = 20.0 Hz). Example 23: Suzuki coupling reaction involving fluorinated aryl borate esters, details of which are as follows:

[0036] The fluorinated arylboronic acid ester substrate prepared in Example 5 (0.5 mmol), iodobenzene (0.6 mmol), Pd(OAc)2 (0.01 mmol), ligand SPhos (0.02 mmol), and inorganic base K3PO4 (1.0 mmol) were added to a reaction flask and heated to reflux in a toluene / water mixture (3 mL, 10 / 1). After the reaction was complete, conventional post-processing and separation were performed to obtain the corresponding fluorobiphenyl derivatives with a separation yield of 81%. 1 H NMR (100 MHz, CDCl3) δ 7.79 (dd, J = 5.0, 2.4 Hz, 1H), 7.63 - 7.55 (m, 3H), 7.48 - 7.35 (m, 8H), 7.32 (t, J = 8.1 Hz, 1H). 13CNMR (101 MHz, CDCl3) δ 159.36 (d, J = 252.1 Hz), 140.43, 135.96 (d, J = 8.1Hz), 135.19 (d, J = 3.1 Hz), 130.45 (d, J = 20.0 Hz), 130.02 (d, J = 7.9 Hz),129.21 (d, J = 8.1 Hz), 129.06, 128.52, 128.05 (d, J = 2.8 Hz), 127.92,127.34, 114.15 (d, J = 19.8 Hz). The various aspects, embodiments, technical features, and specific examples covered in this invention are all used to illustrate the technical solutions of this invention and are merely illustrative examples, not intended to limit the invention. The scope of protection of this invention is defined only by the appended claims. Those skilled in the art can make various modifications, substitutions, optimizations, and extended applications to this invention without departing from its core spirit and scope of protection, resulting in equivalent technical solutions, all of which fall within the scope of protection of this invention.

[0037] The chapter and title divisions in this invention are only for the convenience of text organization and reading, and do not constitute a limitation on the technical solutions of this invention. The technical content disclosed in each chapter can be adapted to and applied to any technical solution, embodiment and technical feature of this invention.

[0038] In this invention, if open-ended terms such as "comprising," "including," or "having" are used to define the composition components or process steps, their meaning simultaneously covers the corresponding closed-ended and semi-closed-ended definitions. That is, the composition disclosed in this invention may be composed of the said components or substantially composed of the said components, and the preparation process disclosed in this invention may be composed of the said steps or substantially composed of the said steps.

[0039] It should be noted that the order of the process steps described in this invention is not the only possible order of execution. As long as the technical effect of this invention can be achieved and the technical solution can be implemented, the execution order of each step can be adjusted, and two or more steps can be executed simultaneously or in parallel, all of which fall within the scope of protection of this invention.

[0040] Those skilled in the art should understand that, without departing from the essential technical solution and protection scope of this invention, any modifications, deletions, additions, or substitutions can be made to the embodiments of this invention, or substantially equivalent technical features can be used to replace the technical features in the embodiments of this invention. Furthermore, the technical solution of this invention can be adaptively optimized according to actual application scenarios and material characteristics. Therefore, this invention is not limited to the specific embodiments disclosed herein; all technical solutions falling within the protection scope of the claims of this invention are within the protection scope of this invention.

Claims

1. A fluorinated arylboronic acid ester compound, characterized in that, Its structural formula is shown in Equation I below: ; In Formula I: R is selected from hydrogen, halogen, alkoxy, alkyl, acyloxy, aryl, siloxy, or ester; Ar is a benzene ring or a naphthalene ring.

2. The fluorinated arylboronic acid ester compound according to claim 1, characterized in that, R is hydrogen, fluorine, chlorine, alkoxy with 1-6 carbon atoms, acyloxy with 1-7 carbon atoms, alkyl with 1-6 carbon atoms, benzene ring with chemically acceptable substituents, pyridine ring with chemically acceptable substituents, pyrrole ring with chemically acceptable substituents, tert-butyldimethylsiloxy, triisopropylsiloxy, alkoxycarbonyl with 1-6 carbon atoms, or alkylcarbamoyl with 1-7 carbon atoms.

3. A method for preparing the fluorinated arylboronic acid ester compound according to claim 1 or 2, characterized in that, The specific steps are as follows: Under nitrogen / argon protection, in a solvent, a fluorinated aryl base compound of formula II and a compound of formula III, bis(4,4,5,5-tetraethyl-1,3,2-dioxaborpentane-2-yl)methane, are heated and reacted in an organic solvent with the aid of an alkali. The resulting reaction solution is then post-treated to obtain the fluorinated aryl borate ester compound shown in formula I. The structural formula of the fluorinated aromatic base material of compound II is as follows: ; The structural formula of compound III, bis(4,4,5,5-tetraethyl-1,3,2-dioxaborone-2-yl)methane, is as follows: ; Wherein, R is selected from hydrogen, halogen, alkoxy, alkyl, acyloxy, aryl, siloxy, ester or amide; Ar is a benzene ring, naphthyl ring or pyridine ring.

4. The method for preparing a fluorinated arylboronic acid ester compound according to claim 3, characterized in that, The molar ratio between the fluorinated aromatic base of Formula II, the bis(4,4,5,5-tetraethyl-1,3,2-dioxaborpentane-2-yl)methane of Formula III, and the base is 1 : (2-3) : (1-2).

5. The method for preparing a fluorinated arylboronic acid ester compound according to claim 3, characterized in that, The temperature of the heating reaction is 80-120°C. o C, the heating reaction time is 5-24 hours.

6. The method for preparing a fluorinated arylboronic acid ester compound according to claim 3, characterized in that, The alkali is one or more of NaOtBu, KOtBu, NaOMe, KOMe, KOAc, KHMDS, or NaHMDS.

7. The method for preparing a fluorinated arylboronic acid ester compound according to claim 3, characterized in that, The organic solvent is one or more of tetrahydrofuran, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, 1,4-dioxane, or toluene.

8. The method for preparing a fluorinated arylboronic acid ester compound according to claim 3, characterized in that, The molar ratio of the fluorinated aromatic base of Formula II, the compound of Formula III (bis(4,4,5,5-tetraethyl-1,3,2-dioxaborpentane-2-yl)methane), and the base is 1:2:2; the heating reaction temperature is 120°C. o C, the heating reaction time is 12 hours; the base is KOtBu; the organic solvent is ethylene glycol dimethyl ether.

9. The application of a fluorinated arylboronic acid ester compound as described in claim 1 or 2, characterized in that, Fluorinated aryl borate esters represented by Formula I are used as synthetic intermediates to prepare fluorinated aryl derivatives through a borate ester group conversion reaction.

10. The application according to claim 9, characterized in that, The conversion reaction of the borate ester group is a halogenation reaction, which includes at least one of copper-promoted chlorination, bromination, and iodination; or the conversion reaction of the borate ester group is a Suzuki coupling reaction, which converts the borate ester group into an aryl substituent.